




Hvidovre
Hospital



AUTOMATICALLY ADJUSTING OXYGEN IN RESPONSE TO SATURATION DURING ACTIVITY

In patients with COPD



Linette Marie Kofod, Physiotherapist, PhD student


PMR-C, Department of Physio- and Occupational Therapy, Hvidovre Hospital, DK 🇩🇰 and
Faculty of Medicine and Health, Örebro University, Sweden 🇸🇪

I have no conflicts of interest.





**Before
1917**



Dosing oxygen
 O_2 in l/min

Saturation = SpO_2





Iltbehandling til den akut syge voksne patient

Overvej restriktiv og målrettet iltbehandling til den akut syge voksne patient med nedsat iltmætning.

BTS GUIDELINE FOR OXYGEN USE
IN ADULTS IN HEALTHCARE AND
EMERGENCY SETTINGS

- ▶ These staff should use appropriate devices and flow rates in order to achieve the target saturation range (figure 2 (chart 2)).

Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis



Derek K Chu^{*†}, Lisa H-Y Kim^{*†}, Paul J Young, Nima Zamiri, Saleh A Almenawer, Roman Jaeschke, Wojciech Szczeklik, Holger J Schünemann, John D Neary, Waleed Alhazzani

Summary

Background Supplemental oxygen is often administered liberally to acutely ill adults, but the credibility of the evidence for this practice is unclear. We systematically reviewed the efficacy and safety of liberal versus conservative oxygen therapy in acutely ill adults. *Lancet* 2018; 391: 1693–705
See [Comment](#) page 1640
* Contributed equally

Methods In the Improving Oxygen Therapy in Acute-illness the Cochrane Central Register of Controlled Trials, MEDLINE, WHO International Clinical Trials Registry from inception liberal and conservative oxygen therapy in acutely ill adult respiratory diseases or psychiatric disease, patients on extracorporeal oxygen therapy or elective surgery were excluded. We screened and in duplicate. We also extracted individual patient-level mortality (in-hospital, at 30 days, and at longest follow-up), hospital-acquired pneumonia, any hospital-acquired infection, and meta-analyses. We assessed quality of evidence using the grading of recommendations assessment, development, and evaluation approach. This study is registered with PROSPERO, number CRD42017065697.


Findings 25 randomised controlled trials enrolled 16 037 patients with sepsis, critical illness, stroke, trauma, myocardial infarction, or cardiac arrest, and patients who had emergency surgery. Compared with a conservative oxygen strategy, a liberal oxygen strategy (median baseline saturation of peripheral oxygen [SpO₂] across trials, 96% [range 94–99%, IQR 96–98]) increased mortality in-hospital (relative risk [RR] 1·21, 95% CI 1·03–1·43, *P*=0·00, high quality), at 30 days (RR 1·14, 95% CI 1·01–1·29, *I*²=0%, high quality), and at longest follow-up (RR 1·10, 95% CI 1·00–1·20, *I*²=0%, high quality). Morbidity outcomes were similar between groups. Findings were robust to trial sequential, subgroup, and sensitivity analyses.

16,037 patients with stroke, sepsis, myocardial infarction or critical illness:
A mortality increase of 21 % with liberal oxygen treatment compared to less oxygen dose (SAT 92–96 %).


(Prof R Jaeschke, Prof H J Schünemann, W Alhazzani), McMaster University, Hamilton, ON, Canada; Medical Research Institute of New Zealand, Wellington, New Zealand (P J Young MBChB); Intensive Care Unit, Wellington Regional Hospital, Wellington, New Zealand (P J Young); and Department of Intensive Care and Perioperative Medicine,

**Dosing oxygen in the stable setting:
Patients with COPD needing home oxygen**

Target saturation: 90-94%



The Oxygen dose is
determined based on an
arterial blood gas analysis –
taken AT REST



EXERCISING WITH COPD

Oxygen need increases



Desaturation




Hypoxemia




Dyspnea



Activity stop





O2Matic = automated oxygen titration




METHODE

Randomized Crossover double-blind study

N= 33 patients

The Endurance Shuttle Walk Test = ESWT



'From 0–10, how much difficulty is your breathing causing you right now?'




Dyspnea score (Borg CR10);
The minimal clinically important difference is 1 point in the Borg score

N=33	Usual oxygen dose	Target saturation	
	Fixed-dose	Automated dose	P-value
Dyspnea score, 0-10	8 (5–9)	4 (3–6)	<0.001
Walking time in minutes	5.5 (3.3–7.9)	10.9 (6.5–14.9)	<0.001

Results

Results



Avg. oxygen dose (l/min)		
Fixed-dose	Automatic dose	P-value
1.6 ±0.9	7.9 ±3.1	<0.001

Konklusion



✓ More well-matched oxygen demand

✓ 50% reduction in perceived dyspnea

✓ Walking distance 98% increase

Automatic oxygen titration versus constant oxygen flow rates during walking in COPD: a randomised controlled, double-blind, crossover trial

Tessa Schneeberger,^{1,2} Inga Jarosch,^{1,2} Daniela Leitl,^{1,2} Rainer Gloeckl,^{1,2} Wolfgang Hitzl,^{3,4,5} Clancy John Dennis,⁶ Tatjana Geyer,⁷ Carl-Peter Criée,⁸ Andreas Rembert Koczulla,^{1,2,9,10} Klaus Kenn^{1,2,9}

50 patients with COPD and LTOT



CONCLUSION

As shown by this randomised, double-blinded, crossover trial, we found that the use of an automatically titrating supplemental O₂-system, capable of adjusting O₂-flows during exercise in response to SpO₂, leads to significantly and clinically relevant improvements in walking endurance time, oxygenation and dyspnoea compared with an individually, exercise titrated constant O₂-flow system as commonly used in practice.

No impact on PCO₂



Automated devices to keep target saturation







EF Hansen et al. Eur Clin Resp J 2020

COVID-19, 19 patients, 987 h

Automated devices to keep target saturation







J Harper et al. BMJ Open Resp Res 2021

Critical ill, 20 patients, 23 h

Automated
devices to keep
target
saturation







Automated devices to keep target saturation

F Lellouche et al. Int J COPD 2016

AECOPD, 50 patients




Automated devices to keep target saturation



L'Her et al. Eur Respir J 2017

Emergency room, 190 patients, 3 h


	FreeO ₂	Manual O ₂	Adjusted difference (95% CI)	p-value
Primary outcome				
Time within SpO ₂ range %				
Total	81.3±20.7	51.8±30.0	29.4 (25.7; 33.2)	<0.001
Hypoxaemic respiratory failure	82.8±18.5	56.8±29.3	26.0 (20.5; 31.5)	<0.001
Hypercapnic respiratory failure	77.0±25.7	38.3±28.4	38.7 (19.9; 57.4)	<0.001
Secondary outcomes				
Time with hypoxaemia %				
Total	3.2±8.9	5.1±11.5	2.0 (0.1; 3.9)	0.04



P<0.001

Automated devices to keep target saturation

Changes in Symptom Intensities within and Between Intervention and Control Group				
Variable	Within intervention-group changes; median [IQR]	Within control-group changes; median [IQR]	Difference in median change between the intervention and the control group	p-Value for between groups differences
Dyspnea overall unpleasantness, scale AI MDP (range 0–10)				
Dyspnea overall unpleasantness	–5 [–6: –2]	–2 [–6: 0]	–3	0.003*
Intensity of five sensory qualities on the MDP (item range 0–10)				
Physical breathing effort	–3 [–6: 0]	–1 [–3: 1]	–2	0.005*
Air hunger	–4 [–7: –1.25]	–1 [–3: 0]	–3	<0.001*
Chest tightness	–1 [–5: 0]	0 [–1: 0]	–1	<0.001*
Mental breathing effort	–4 [–7: 0]	–1 [–4: 0.5]	–3	0.029*
Hyperpnea	–3 [–6: 0]	–2 [–4.5: 0]	–1	0.032*



We know that...

Acute setting

- A target saturation is beneficial
 - + Mortality
 - +Dyspnea
- Automated oxygen devices keep the patients better in target interval



Non-acute setting


- Target saturation during physical tests
 - + Dyspnea
 - + Exercise capacity

At home




Automatic home oxygen treatment

A pilot randomized crossover feasibility trial
12 patients




DaiLiHOT – part 2




1-5 l/min



1-8 l/min





We know, that

- ⚡ Oxygen treatment decreases mortality
- ⚡ Avoiding hyperoxemia and hypoxemia in an acute setting decreases mortality and dyspnea

We do not know, if

- ⚡ hypoxemia- and hyperoxemia- “fluctuations” affect the health in stable COPD
- ⚡ Target saturation during daily life would be beneficial for the patient with stable COPD



But we are going to investigate it...

Ilbmætte

Study team:

Elisabeth Westerdal, PT, PhD

Morten Tange Kristensen, PT, PhD, professor


Barbara Cristina Brocki, PT, PhD

Dorthe Gaby Dove, RN, PhD

Thomas Ringbæk, MD, DMSc

Ejvind Frausing Hansen, MD

Linette



Funding:

- The Association of Danish Physiotherapists Research Fund
- Innovation Fund Denmark
- The Research Fund of Amager and Hvidovre Hospital
- Svensk Lungemedicinsk Forening (SLMF)

